• Journal of radiological science and technology
• /
• v.28 no.2
• /
• pp.117-122
• /
• 2005

According to the Para. 5 of Art 2 of the Korean Nuclear Safety Regulations, which was revised in 1999, internal dose assessment as well as external one should be performed by law for employees at a nuclear power plant from 2003, and their estimate errors should also be within 50%. Thus, more accurate internal dosimetry becomes important. Corresponding to such regulation revision, we are developing a more accurate thyroid-uptake internal dosimetric system and have developed a Monte Carlo simulation code, the so-called CALEFF, to calculate the detection efficiency of the dosimetric system. In this paper, we calculated detection efficiencies with various test conditions by using the CALEFF code and discussed their characteristics. We may use the detection efficiency calculated by the code in calibrating the thyroid internal dose from measured data.

• Journal of radiological science and technology
• /
• v.34 no.3
• /
• pp.209-214
• /
• 2011

Goal of this study was to measure effective radiation dose of highly exposed patients who were treated by TACE, interventional radiology from June to September 2010. The effective radiation dose was approximately measured by weighted DAP (dose area product) with the ionization chamber which is inserted in angiography equiment (Philips Allura Xper FD 20). Radiation dose was measured by TLD which was attached to patients' thyroid and genital gland. The average of ED (effective dose) was 18.43${\pm}$6.63 mSv per person and the average of radiation dose of thyroid and genital gland was 0.37 mSv, 0.77 mSv, respectively. The mean radiation dose of operators who wear the protector was 0.07 mSv for thyroid, and 0.01 mSv for genital gland, respectively. All staffs involved in TACE treatment, have to keep them aware and use the appropriate protectors to reduce the radiation dose of patient.

• Asian Pacific Journal of Cancer Prevention
• /
• v.17 no.3
• /
• pp.1115-1118
• /
• 2016

Background: There is controversy about ablation efficacy of low or high doses of radioiodine-131 (RAI) in patients with differentiated thyroid cancers (DTC). The purpose of this prospective study was to determine efficacy of 30 mCi and 100 mCi of RAI to achieve successful ablation in patients with low to intermediate risk DTC. Materials and Methods: This prospective cross sectional study was conducted from April 2013 to November 2015. Inclusion criteria were patients of either gender, 18 years or older, having low to intermediate risk papillary and follicular thyroid cancers with T1-3, N0/N1/Nx but no evidence of distant metastasis. Thirty-nine patients were administered 30 mCi of RAI while 61 patients were given 100 mCi. Informed consent was acquired from all patients and counseling was done by nuclear physicians regarding benefits and possible side effects of RAI. After an average of 6 months (range 6-16 months; 2-3 weeks after thyroxin withdrawal), these patients were followed up for stimulated TSH, thyroglobulin (sTg) and thyroglobulin antibodies, ultrasound neck (U/S) and a diagnostic whole body iodine scan (WBIS) for ablation outcome. Successful ablation was concluded with stimulated Tg< 2ng/ml with negative antibodies, negative U/S and a negative diagnostic WBIS (triple negative criteria). ROC curve analysis was used to find diagnostic strength of baseline sTg to predict successful ablation. Results: Successful ablation based upon triple negative criteria was 56% in the low dose and 57% in the high dose group (non-significant difference). Based on a single criterion (follow-up sTg<2 ng/ml), values were 82% and 77% (again non-significant). The ROC curve revealed that a baseline sTg level ${\leq}7.4ng/ml$ had the highest diagnostic strength to predict successful ablation in all patients. Conclusions: We conclude that 30 mCi of RAI has similar ablation success to 100 mCi dose in patients with low to intermediate risk DTC. A baseline $sTg{\leq}7.4ng/ml$ is a strong predictor of successful ablation in all patients. Low dose RAI is safer, more cost effective and more convenient for patients and healthcare providers.

• Journal of the Korean Society of Radiology
• /
• v.16 no.3
• /
• pp.351-356
• /
• 2022

The purpose of this study was to evaluate the cancer incidence rate and provide basic data by measuring the photoneutron dose generated during intensity-modulated radiation therapy and volumetric modulated arc therapy used in radiation therapy for prostate cancer. The optically stimulated luminescence albedo neutron dosimeter for neutron measurement was placed on the Rando phantom in the abdomen and thyroid and photoneutron dose generated was measured. As a result of the study, intensity-modulated radiation therapy (7 portal) was measured to be higher than volumetric rotational radiation therapy in both abdominal and thyroid locations. When the cancer incidence rate was evaluated using the nominal risk coefficient of ICRP 103, the cancer incidence rate due to exposure to the colon and thyroid during intensity-modulated radiation therapy was 9.9 per 1,000 people, and volumetric rotational radiation therapy for 1,000 people. It was 3.5 per person. Based on the principle of ALARA (As low as reasonably archievable), it is considered to be a guideline for minimizing the exposure dose to normal organs in the establishment of a radiation treatment plan.

• Nuclear Medicine and Molecular Imaging
• /
• v.41 no.3
• /
• pp.218-225
• /
• 2007

Purpose: Postoperative thyroid remnant radioablation therapy is necessary to reduce the recurrence and mortality rates as well as to prepare the patients for a proper long term surveillance of well-differentiated thyroid cancers. The radiation safety rules of the government require the patient to be isolated in a hospital if the expected radiation exposure to the family members would be greater than 5 mSv (500 mRem). The purpose was to measure the radiation received by the family members of patients who received large doses of NaI-131. Material and Methods: We have administered 12 therapy doses ranging from 3.70-5.55 GBq (100 to 150 mCi) to 11 patients, and released them immediately if they met the radiation safety criteria. Informed consent was obtained from the subjects prior to the therapy, and each of them agreed to follow written radiation safety instructions. TLD badges were used to measure the radiation dose received by the family members and the room adjacent to the patient's bed room during the first 72 hours. Results: The average dose received by the family members who spent the most time in the closest distance with the patients was 0.04 mSv with a range of 0.01-0.17 mSv. Even the highest dose was only about 3% of the limit set by the government. The average radiation dose to the outer wall of the patient's room was 0.15 mSv. Conclusion: It is concluded that I-131 ablation therapy can be administered to outpatients safely to thyroid cancer patients who meet the established radiation safety criteria and follow the instructions.

• Nuclear Engineering and Technology
• /
• v.54 no.12
• /
• pp.4698-4707
• /
• 2022

As part of the ICRP Task Group 103 project, we developed ten thyroid models for the pediatric mesh-type reference computational phantoms (MRCPs). The thyroid is not only a radiosensitive target organ needed for effective dose calculation but an important source region particularly for radioactive iodines. The thyroid models for the pediatric MRCPs were constructed by converting those of the pediatric voxel-type reference computational phantoms (VRCPs) in ICRP Publication 143 to a high-quality mesh format, faithfully maintaining their original topology. At the same time, we improved several anatomical parameters of the thyroid models for the pediatric MRCPs, including the mass, overlying tissue thickness, location, and isthmus dimensions. Absorbed doses to the thyroid for the pediatric MRCPs for photon external exposures were calculated and compared with those of the pediatric VRCPs, finding that the differences between the MRCPs and VRCPs were not significant except for very low energies (<0.03 MeV). Specific absorbed fractions (target ⟵ thyroid) for photon internal exposures were also compared, where significant differences were frequently observed especially for the target organs/tissues close to the thyroid (e.g., a factor of ~1.2-~327 for the thymus as a target) due mainly to anatomical improvement of the MRCP thyroid models.

• Journal of radiological science and technology
• /
• v.33 no.3
• /
• pp.269-276
• /
• 2010

This study attempts to propose ways to optimize and improve the period of hospitalization for the radioiodine treatment by calculating the dose rate of patients treated with high-dose radioiodine by distance and time slot. As a result, 24 hours after the patient was treated with 100 mCi high-dose iodine, the dose rate was attenuated to $1,035{\mu}Sv/hr$ at the navel, to $109{\mu}Sv/hr$ at 50 cm, and to $33{\mu}Sv/hr$ at 100 cm. 24 hours after the patient was treated with 150 mCi high-dose iodine, the dose rate was attenuated to $637{\mu}Sv/hr$ at the navel, to $100{\mu}Sv/hr$ at 50 cm, and to $40{\mu}Sv/hr$ at 100 cm. 24 hours after the patient was treated with 180 mCi high-dose iodine, the dose rate was attenuated to $1,251{\mu}Sv/hr$ at the navel, $140{\mu}Sv/hr$ at 50 cm, and to $56{\mu}Sv/hr$ at 100 cm. In light of the current criterion for discharge recommended by the US Nuclear Regulatory Commission being $70.4{\mu}Sv/hr$, the present study indicates earlier discharge is feasible by applying a new scheme. This suggests that the proposed scheme in this study will help to solve the problem of shortage of treatment beds with the increasing trend of patients with thyroid cancer taken into consideration.

• Imaging Science in Dentistry
• /
• v.30 no.1
• /
• pp.11-15
• /
• 2000

Purpose: The primary objective of this study was to estimate the radiation absorbed doses in certain critical organs in the head and neck region with an Orthopos plus, a Panelipse, and a Panex-E machines. The second objective was to compare the absorbed doses between 5 inch by 12 inch and 6 inch by 12 inch image field for the Orthopos plus. Materials and Methods: Rando phantom and LiF TLD chips were used for dosimetry. The absorbed doses were measured at the thyroid gland, the submandibular gland, the parotid gland, the mouth floor, the maxillary sinus, the brain, the mandibular body, the mandibular ramus, the 2nd cervical spine and the skin over TMJ area. Results: The highest absorbed dose value was recorded at the mandibular ramus for the Orthopos plus with narrow image field. Higher absorbed dose values were recorded at the parotid gland, the mouth floor, the submandibular gland, and the 2nd cervical spine. The doses in the parotid gland were 597 μGy and 529 μGy with Orthopos plus, 638 μGy with Panelipse, and 1094μGy with Panex-E. Corresponding figures for the mandibular ramus were 2363 Gy and 1220 μGy, 248 μGy, and 118 μGy. The absorbed doses to the thyroid gland, the maxillary sinus, the brain, and the skin over TMJ were very low. Conclusion: Higher exposure values were recorded for the Orthopos plus than Panelipse and Panex-E. There was no significant differences of the absorbed doses according to the image field size.

• Journal of Radiation Protection and Research
• /
• v.32 no.2
• /
• pp.45-50
• /
• 2007

In this study, uptake rates of internal organs and daily urinary excretion rates were measured to get more reliable estimation results for Korean. Radioactive iodine($^{131}I$) of $100{\mu}Ci$ was administered by ingestion to 28 adult males for the experiment and then the radioactivity in thyroid gland, liver, stomach, small intestine, kidneys, and urine was measured after time intervals of 2, 4, 6 and 24 hours. Uptake rates of each organ and daily urinary excretion rates were calculated on the basis of these experimental results. As a result, uptake rates of 19.70% for thyroid and daily urinary excretion rates of 71.12%, on the average, were indicated. The maximum of uptake rates and daily urinary excretion rates were recorded after 2 hours of administration of $^{131}I$, but those rates were decreased gradually later. It was also found that uptake rates were the highest in stomach, followed by the left kidney, liver, small intestine and right kidney except for thyroid gland. In this experiment, the calculated uptake change rate in thyroid gland after 24 hours of administration of $^{131}I$ was different from that of ICRP-54/67(30%) and ICRP-78(25%). Thus, it is necessary to apply more reliable approach, reflecting the characteristic of Korean physiology and to obtain the basic data of results using this approach for calculation of the internal adsorbed dose. In the future, this approach can be helpful for the internal dose assessment of radiation workers in a nuclear power plant or in a hospital.

• Journal of Yeungnam Medical Science
• /
• v.40 no.1
• /
• pp.12-22
• /
• 2023

Graves disease (GD) is the most common cause of hyperthyroidism, accounting for more than 90% of cases in Korea. Patients with GD are treated with any of the following: antithyroid drugs (ATDs), radioactive iodine (RAI) therapy, or thyroidectomy. Most patients begin treatment with ATDs, and clinical guidelines suggest that the appropriate treatment period is 12 to 18 months. While RAI treatment and surgery manage thyrotoxicosis by destroying or removing thyroid tissue, ATDs control thyrotoxicosis by inhibiting thyroid hormone synthesis and preserving the thyroid gland. Although ATDs efficiently control thyrotoxicosis symptoms, they do not correct the main etiology of GD; therefore, frequent relapses can follow. Recently, a large amount of data has been collected on long-term ATDs for GD, and low-dose methimazole (MMZ) is expected to be a good option for remission. For the long-term management of recurrent GD, it is important to induce remission by evaluating the patient's drug response, stopping ATDs at an appropriate time, and actively switching to surgery or RAI therapy, if indicated. Continuing drug treatment for an extended time is now encouraged in patients with a high possibility of remission with low-dose MMZ. It is also important to pay attention to the quality of life of the patients. This review aimed to summarize the appropriate treatment methods and timing of treatment transition in patients who relapsed several times while receiving treatment for GD.